A. Séguin

Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine

L. Moulton, F. Polack, G. Pérez Marc, 2022, The New England journal of medicine.

Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

T. Vesikari, A. Makarkov, S. Pillet, 2020, The Lancet.

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities

D. Vinh, Marc‐André D'Aoust, A. Makarkov, 2022, npj Vaccines.

Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants

Marc‐André D'Aoust, A. Makarkov, S. Pillet, 2020, medRxiv.

Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age.

N. Landry, B. Ward, Julie Couillard, 2021, Vaccine.

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

Marc‐André D'Aoust, A. Makarkov, S. Pillet, 2021, Nature Medicine.

Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03

L. Moulton, F. Polack, Marc‐André D'Aoust, 2022, medRxiv.